Biota Pharmaceuticals Inc (BOTA) 2.60 $BOTA
Biota Pharmaceuticals: Recent Progress Illustrates Buying Opportunity Remains
Daniel Ward - at Seeking Alpha - Tue Feb 10, 10:52AM CST
BOTA: 2.60 (-0.06)
Valuable Updates on Pharmaceutical Companies: New Research on Avalanche Biotechnologies, BioCryst, Biogen, Biota Pharmaceuticals, and Bio-Techne
PR Newswire - Tue Feb 10, 7:30AM CST
Editor Note: For more information about this release, please scroll to bottom.
BIIB: 391.66 (-0.45), BCRX: 10.06 (-0.09), BOTA: 2.60 (-0.06), TECH: 94.61 (+1.83), AAVL: 36.29 (+0.01)
Biota Pharmaceuticals (BOTA) Upgraded From Sell to Hold
at The Street - Mon Feb 09, 9:40AM CST
Biota Pharmaceuticals (BOTA) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C.
BOTA: 2.60 (-0.06)
Biota Pharmaceuticals swings to net income of USD6.5m in Q2 fiscal 2015
M2 - Fri Feb 06, 5:04AM CST
Biopharmaceutical company Biota Pharmaceuticals (NasdaqGS:BOTA) stated on Thursday that its net income was USD6.5m for the three month period ended 31 December 2014.
BOTA: 2.60 (-0.06)
Biota Pharmaceuticals' (BOTA) CEO Joseph Patti on F2Q 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 05, 10:25AM CST
BOTA: 2.60 (-0.06)
Biota Pharmaceuticals beats by $0.28, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 6:07AM CST
BOTA: 2.60 (-0.06)
Biota Pharmaceuticals Reports Second Quarter Fiscal Year 2015 Financial Results
GlobeNewswire - Thu Feb 05, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
today announced its financial results for the three month period ended December 31, 2014, which is the second quarter of the Company's 2015 fiscal year, and also provided an update on recent corporate developments.
BOTA: 2.60 (-0.06)
Biota Pharmaceuticals to Present at the 2015 BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 03, 2:00PM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company" , a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced today that Biota CEO & President Joseph Patti will present a corporate overview at the 2015 BIO CEO & Investor Conference. The presentation will take place on Tuesday, February 10, 2015 at 3:00 p.m. EST at the Waldorf Astoria Hotel in New York, NY.
BOTA: 2.60 (-0.06)
Biota Pharmaceuticals to Host Conference Call to Report Second Quarter Fiscal Year 2015 Financial Results on February 5, 2015
GlobeNewswire - Thu Jan 29, 2:00PM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company" , a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced today that management will host a conference call on Thursday, February 5, 2015 at 9:00 a.m. EST to review the Company's second quarter financial results and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference call.
BOTA: 2.60 (-0.06)
Influenza A and B Infections Global Clinical Trials Review, H2, 2014 - Clinical Trial overview of the Top 10 Companies & Top 8 Institutes
M2 - Tue Jan 06, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/rwt85s/influenza_a_and_b) has announced the addition of the "Influenza A and B Infections Global Clinical Trials Review, H2, 2014" report to their offering. This report provides elemental information and data relating to the clinical trials on Influenza A and B Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Influenza A and B Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Daiichi Sankyo Company, Limited - GlaxoSmithKline plc - F. Hoffmann-La Roche Ltd. - Microgen Scientific Industrial Company for Immunobiological Medicines - Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co Ltd - Crucell N.V. - Biota Pharmaceuticals, Inc. - Biota Holdings Limited (Inactive) - Beech Tree Labs, Inc. - AstraZeneca PLC Clinical Trial Overview of Top Institutes / Government - British Columbia Centre for Disease Control - West China Hospital - Nagasaki Evaluation Organization for Clinical Interventions - TJ-27 Influenza study group - The National Institute of Allergy and Infectious Diseases - Fukuoka University - University of Manitoba - University of Surrey For more information visit http://www.researchandmarkets.com/research/rw...za_a_and_b
BOTA: 2.60 (-0.06), AZN: 69.96 (+0.20), GSK: 47.94 (+1.99)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 11:48AM CST
SD: 2.09 (+0.14), XENT: 23.06 (+0.46), WLL: 38.53 (+2.41), BTE: 19.27 (+0.32), BOTA: 2.60 (-0.06), CNAT: 5.92 (+0.10), WG: 6.69 (+0.28), SN: 15.21 (-0.12), LPI: 13.25 (+0.81), EROC: 2.63 (+0.15), BCLI: 3.86 (-0.02), NDRM: 10.76 (+0.22), SMLR: 4.54 (+0.20), QURE: 19.83 (-0.18), SFY: 2.91 (+0.26), ANTH: 3.84 (+0.06), PLX: 1.84 (-0.04), APRI: 1.84 (-0.08), STXS: 2.27 (+0.13), GST: 2.89 (unch)
Biotech Weekly: Top Value Biotech Picks For 2015
Daniel Ward - at Seeking Alpha - Mon Jan 05, 8:01AM CST
ROSG: 3.65 (+0.32), ECYT: 5.26 (-0.02), TRGT: 2.50 (-0.01), OGXI: 2.06 (-0.05), BOTA: 2.60 (-0.06), XBI: 203.40 (+1.36), DARA: 0.79 (unch), RGDO: 1.17 (+0.02), REPH: 3.13 (-0.12)
Enterococcus Faecium Infections - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xw7rg5/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Enterococcus Faecium Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Dainippon Sumitomo Pharma Co., Ltd. - Melinta Therapeutics, Inc - ConjuGon, Inc. - Omnia Molecular Ltd. - ContraFect Corporation - Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/xw...terococcus
BOTA: 2.60 (-0.06)
Biotech Weekly: Here Come The Institutional Holdings Updates
Daniel Ward - at Seeking Alpha - Mon Nov 17, 7:31AM CST
LOXO: 11.91 (-0.24), TRGT: 2.50 (-0.01), BOTA: 2.60 (-0.06), XBI: 203.40 (+1.36), IBB: 323.46 (+3.04), BIOS: 6.04 (-0.06), RGDO: 1.17 (+0.02), EXEL: 2.48 (+0.20), AMPH: 12.76 (+0.02)
Biota Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company" today announced its financial results for the three month period ended September 30, 2014, which is the first quarter of the Company's 2015 fiscal year, and provided an update on recent corporate developments.
BOTA: 2.60 (-0.06)
Biota Pharmaceuticals to Host Conference Call to Report First Quarter Financial Results on November 7, 2014
GlobeNewswire - Tue Oct 28, 4:00PM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company" announced today that management will host a conference call on Friday, November 7, 2014 at 9:00 a.m. EST to review the Company's first quarter financial results and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results on the same day, prior to the conference call.
BOTA: 2.60 (-0.06)
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Sep 26, 8:12AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
MACK: 10.22 (+0.40), BOTA: 2.60 (-0.06), RGDO: 1.17 (+0.02)
Biota Pharmaceuticals Reports Fourth Quarter and Fiscal Year-End 2014 Financial Results and Corporate Update
GlobeNewswire - Fri Sep 26, 6:01AM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company" today announced financial results for its fourth quarter and fiscal year ended June 30, 2014, and provided an update on a number of recent corporate developments.
BOTA: 2.60 (-0.06)
Biota Pharmaceuticals Announces Changes to Management and Board of Directors
GlobeNewswire - Fri Sep 26, 6:00AM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company" today announced a number of changes to management and its board of directors that will become effective October 1, 2014.
BOTA: 2.60 (-0.06)
Biota Pharmaceuticals to Host Conference Call to Report Fourth Quarter and Year-End 2014 Financial Results on September 26, 2014
GlobeNewswire - Mon Sep 15, 3:39PM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company" announced today that it will host a conference call on Friday, September 26, 2014 at 9:00 a.m. EDT to review the Company's fourth quarter and year-end 2014 financial results and provide an update on recent corporate developments. The Company will issue a press release regarding its financial results on the same day, prior to the conference call.
BOTA: 2.60 (-0.06)
Biota Pharmaceuticals: Recent Progress Illustrates Buying Opportunity Remains
Daniel Ward - at Seeking Alpha - Tue Feb 10, 10:52AM CST
BOTA: 2.60 (-0.06)
Valuable Updates on Pharmaceutical Companies: New Research on Avalanche Biotechnologies, BioCryst, Biogen, Biota Pharmaceuticals, and Bio-Techne
PR Newswire - Tue Feb 10, 7:30AM CST
Editor Note: For more information about this release, please scroll to bottom.
BIIB: 391.66 (-0.45), BCRX: 10.06 (-0.09), BOTA: 2.60 (-0.06), TECH: 94.61 (+1.83), AAVL: 36.29 (+0.01)
Biota Pharmaceuticals (BOTA) Upgraded From Sell to Hold
at The Street - Mon Feb 09, 9:40AM CST
Biota Pharmaceuticals (BOTA) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C.
BOTA: 2.60 (-0.06)
Biota Pharmaceuticals swings to net income of USD6.5m in Q2 fiscal 2015
M2 - Fri Feb 06, 5:04AM CST
Biopharmaceutical company Biota Pharmaceuticals (NasdaqGS:BOTA) stated on Thursday that its net income was USD6.5m for the three month period ended 31 December 2014.
BOTA: 2.60 (-0.06)
Biota Pharmaceuticals' (BOTA) CEO Joseph Patti on F2Q 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 05, 10:25AM CST
BOTA: 2.60 (-0.06)
Biota Pharmaceuticals beats by $0.28, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 6:07AM CST
BOTA: 2.60 (-0.06)
Biota Pharmaceuticals Reports Second Quarter Fiscal Year 2015 Financial Results
GlobeNewswire - Thu Feb 05, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
today announced its financial results for the three month period ended December 31, 2014, which is the second quarter of the Company's 2015 fiscal year, and also provided an update on recent corporate developments. BOTA: 2.60 (-0.06)
Biota Pharmaceuticals to Present at the 2015 BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 03, 2:00PM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
, a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced today that Biota CEO & President Joseph Patti will present a corporate overview at the 2015 BIO CEO & Investor Conference. The presentation will take place on Tuesday, February 10, 2015 at 3:00 p.m. EST at the Waldorf Astoria Hotel in New York, NY. BOTA: 2.60 (-0.06)
Biota Pharmaceuticals to Host Conference Call to Report Second Quarter Fiscal Year 2015 Financial Results on February 5, 2015
GlobeNewswire - Thu Jan 29, 2:00PM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
, a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced today that management will host a conference call on Thursday, February 5, 2015 at 9:00 a.m. EST to review the Company's second quarter financial results and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference call. BOTA: 2.60 (-0.06)
Influenza A and B Infections Global Clinical Trials Review, H2, 2014 - Clinical Trial overview of the Top 10 Companies & Top 8 Institutes
M2 - Tue Jan 06, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/rwt85s/influenza_a_and_b) has announced the addition of the "Influenza A and B Infections Global Clinical Trials Review, H2, 2014" report to their offering. This report provides elemental information and data relating to the clinical trials on Influenza A and B Infections. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Influenza A and B Infections. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Daiichi Sankyo Company, Limited - GlaxoSmithKline plc - F. Hoffmann-La Roche Ltd. - Microgen Scientific Industrial Company for Immunobiological Medicines - Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co Ltd - Crucell N.V. - Biota Pharmaceuticals, Inc. - Biota Holdings Limited (Inactive) - Beech Tree Labs, Inc. - AstraZeneca PLC Clinical Trial Overview of Top Institutes / Government - British Columbia Centre for Disease Control - West China Hospital - Nagasaki Evaluation Organization for Clinical Interventions - TJ-27 Influenza study group - The National Institute of Allergy and Infectious Diseases - Fukuoka University - University of Manitoba - University of Surrey For more information visit http://www.researchandmarkets.com/research/rw...za_a_and_b
BOTA: 2.60 (-0.06), AZN: 69.96 (+0.20), GSK: 47.94 (+1.99)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 11:48AM CST
SD: 2.09 (+0.14), XENT: 23.06 (+0.46), WLL: 38.53 (+2.41), BTE: 19.27 (+0.32), BOTA: 2.60 (-0.06), CNAT: 5.92 (+0.10), WG: 6.69 (+0.28), SN: 15.21 (-0.12), LPI: 13.25 (+0.81), EROC: 2.63 (+0.15), BCLI: 3.86 (-0.02), NDRM: 10.76 (+0.22), SMLR: 4.54 (+0.20), QURE: 19.83 (-0.18), SFY: 2.91 (+0.26), ANTH: 3.84 (+0.06), PLX: 1.84 (-0.04), APRI: 1.84 (-0.08), STXS: 2.27 (+0.13), GST: 2.89 (unch)
Biotech Weekly: Top Value Biotech Picks For 2015
Daniel Ward - at Seeking Alpha - Mon Jan 05, 8:01AM CST
ROSG: 3.65 (+0.32), ECYT: 5.26 (-0.02), TRGT: 2.50 (-0.01), OGXI: 2.06 (-0.05), BOTA: 2.60 (-0.06), XBI: 203.40 (+1.36), DARA: 0.79 (unch), RGDO: 1.17 (+0.02), REPH: 3.13 (-0.12)
Enterococcus Faecium Infections - Pipeline Review, H1 2014
M2 - Mon Dec 08, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xw7rg5/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Enterococcus Faecium Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Dainippon Sumitomo Pharma Co., Ltd. - Melinta Therapeutics, Inc - ConjuGon, Inc. - Omnia Molecular Ltd. - ContraFect Corporation - Biota Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/xw...terococcus
BOTA: 2.60 (-0.06)
Biotech Weekly: Here Come The Institutional Holdings Updates
Daniel Ward - at Seeking Alpha - Mon Nov 17, 7:31AM CST
LOXO: 11.91 (-0.24), TRGT: 2.50 (-0.01), BOTA: 2.60 (-0.06), XBI: 203.40 (+1.36), IBB: 323.46 (+3.04), BIOS: 6.04 (-0.06), RGDO: 1.17 (+0.02), EXEL: 2.48 (+0.20), AMPH: 12.76 (+0.02)
Biota Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
today announced its financial results for the three month period ended September 30, 2014, which is the first quarter of the Company's 2015 fiscal year, and provided an update on recent corporate developments. BOTA: 2.60 (-0.06)
Biota Pharmaceuticals to Host Conference Call to Report First Quarter Financial Results on November 7, 2014
GlobeNewswire - Tue Oct 28, 4:00PM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company"
announced today that management will host a conference call on Friday, November 7, 2014 at 9:00 a.m. EST to review the Company's first quarter financial results and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results on the same day, prior to the conference call. BOTA: 2.60 (-0.06)
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Sep 26, 8:12AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
MACK: 10.22 (+0.40), BOTA: 2.60 (-0.06), RGDO: 1.17 (+0.02)
Biota Pharmaceuticals Reports Fourth Quarter and Fiscal Year-End 2014 Financial Results and Corporate Update
GlobeNewswire - Fri Sep 26, 6:01AM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
today announced financial results for its fourth quarter and fiscal year ended June 30, 2014, and provided an update on a number of recent corporate developments. BOTA: 2.60 (-0.06)
Biota Pharmaceuticals Announces Changes to Management and Board of Directors
GlobeNewswire - Fri Sep 26, 6:00AM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
today announced a number of changes to management and its board of directors that will become effective October 1, 2014. BOTA: 2.60 (-0.06)
Biota Pharmaceuticals to Host Conference Call to Report Fourth Quarter and Year-End 2014 Financial Results on September 26, 2014
GlobeNewswire - Mon Sep 15, 3:39PM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company"
announced today that it will host a conference call on Friday, September 26, 2014 at 9:00 a.m. EDT to review the Company's fourth quarter and year-end 2014 financial results and provide an update on recent corporate developments. The Company will issue a press release regarding its financial results on the same day, prior to the conference call. BOTA: 2.60 (-0.06)
